Bedside measurement of factor VIII:C activity in individuals with hemophilia A

Craig M. Kessler(Georgetown University), Frank M. LaDuca(Edison International (United States)), M. Zucker(Edison International (United States)), S. Ghesani(Edison International (United States)), Zale P. Bernstein(Hemophilia Center of Western Pennsylvania), Z. Shamsipour(Washington University Medical Center), C. Françès(Navarre Institute of Health Research)

American Journal of Hematology

March 1, 1996

10.1002/(sici)1096-8652(199603)51:3<181::aid-ajh1>3.0.co;2-t

Cited by 4

Related Papers

Efficacy of romiplostim in patients with chronic immune thrombocytopenic purpura: a double-blind randomised controlled trial

|The Lancet|2008|862

Long-Term, Low-Intensity Warfarin Therapy for the Prevention of Recurrent Venous Thromboembolism

|New England Journal of Medicine|2003|809

Effects of estrogen or estrogen/progestin regimens on heart disease risk factors in postmenopausal women. The Postmenopausal Estrogen/Progestin Interventions (PEPI) Trial. The Writing Group for the PEPI Trial

|JAMA|1995|605

A Prospective Study of Human Immunodeficiency Virus Type 1 Infection and the Development of AIDS in Subjects with Hemophilia

|New England Journal of Medicine|1989|528

European Dermatology Forum S1‐guideline on the diagnosis and treatment of sclerosing diseases of the skin, Part 1: localized scleroderma, systemic sclerosis and overlap syndromes

|Journal of the European Academy of Dermatology and Venereology|2017|262